A new study presented at ASCO 2026 found that women taking GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound had a lower risk of developing breast cancer. Researchers believe weight loss, reduced inflammation, and improved metabolic health may contribute to the protective effect, though more clinical studies are still needed.